Vanguard Intermediate Term Corporate Bond ETF vs Viatris Inc — how do they compare? Vanguard Intermediate Term Corporate Bond ETF trades at $81.18, while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and Viatris Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| VCIT | VTRS | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $84.82 | $17.86 |
52-Week Low | $81.07 | $9.49 |
Market Cap | — | $18.69B |
Enterprise Value | — | $30.80B |
Dividend Yield | — | 2.95% |
Trailing returns across standard periods
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →